Cooperative Agreement to Support a Human Abuse Potential Study of Botanical Kratom (U01 Clinical Trial Required)
Forecast: not open for applications yet. Dates are the funder's estimate. Save a search and Brieflist marks it when it opens (Grants Pro e-mails you), or get the free weekly digest:
This is a forecast: the funder has announced the grant but applications are not open yet. Dates may change.
The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom.
Read the official page on Grants.gov ↗ Get new grants like this
- Funder
- Food and Drug Administration (Department of Health and Human Services)
- Where
- 🇺🇸 United States
- Status
- Forecast
- Funding
- Up to $2m per award
- Expected awards
- 1
- Who can apply
- Most organisations
- Topics
- Agriculture & food Justice & security
- Opportunity number
- FOR-FD-24-010
- Instrument
- Cooperative agreement
About this grant
The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. FDA has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant indigenous to Southeast Asia. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. Although Kratom use is prevalent, to date, clinical evaluations of its abuse potential have been limited.
The proposed HAP study should be performed in accordance with the guidance for industry, "Assessment of Abuse Potential of Drugs," including (but not limited to) the selection of an appropriate comparator(s) and outcome measures, statistical analyses etc. Interested parties, will also complete the submission of an Investigational New Drug (IND) application and obtain Institutional Review Board (IRB) clearance.
Eligibility
Native American tribal governments (Federally recognized); Special district governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Independent school districts; Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; City or township governments; Public housing authorities/Indian housing authorities; County governments; For profit organizations other than small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Private institutions of higher education. Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →
More from this funder: 12 open opportunities from Food and Drug Administration (FDA).
Applying? Read how to write a winning grant proposal.
Data from Grants.gov, US federal government (public domain). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.